BYSI BeyondSpring Inc.
Price Chart
Executive Summary
BeyondSpring reported Q1 2026 financial results with a net loss from continuing operations of $2.4M, slightly improved from a $2.6M loss in Q1 2025. The pre-revenue clinical-stage biopharma highlighted AACR 2026 preclinical data positioning Plinabulin as a potential backbone ADC combination agent and SEED Therapeutics' advancement of ST-01156 into Phase 1. Cash burn continues with cash and short-term investments declining to $7.9M from $12.6M at year-end 2025, raising financing runway concerns for a $57M market cap company.
Actionable Insight
Monitor cash runway closely — $7.9M in cash provides limited funding for the planned DUBLIN-4 confirmatory Phase 3 trial. The SEED Therapeutics discontinued operations segment swung to a loss, and the prior $35.4M SEED share sale proceeds appear largely consumed. Any financing announcement or partnership deal for Plinabulin would be a significant catalyst.
Key Facts
- Net loss from continuing operations was $2.4M for Q1 2026 vs $2.6M in Q1 2025
- Cash, cash equivalents, and short-term investments fell to $7.9M as of March 31, 2026 from $12.6M at December 31, 2025
- R&D expenses increased to $1.1M from $0.9M year-over-year
- G&A expenses decreased to $1.1M from $1.7M year-over-year
- Discontinued operations (SEED Therapeutics) swung to a $4.3M net loss from $3.8M net income in Q1 2025
- AACR 2026 preclinical data showed Plinabulin enhanced ADC efficacy and tolerability in combination regimens
- SEED Therapeutics completed first dose cohort for ST-01156 Phase 1a RBM39 degrader trial
- No revenue reported for continuing operations
Financial Impact
Cash burn of ~$4.7M in Q1 2026 (continuing ops net loss + discontinued ops net loss), with $7.9M cash runway suggesting ~5-6 quarters of funding at current burn rate
Risk Factors
- Cash runway of $7.9M may be insufficient to fund DUBLIN-4 confirmatory Phase 3 trial without additional financing
- Discontinued operations (SEED) swung to a $4.3M quarterly loss from prior-year income, increasing consolidated cash burn
- Preclinical AACR data may not translate to clinical efficacy in ongoing/planned trials
- No near-term revenue catalysts — company is pre-revenue with no approved products
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-003344 |
| Document: f8k_051326.htm | 0001171843-26-003344 |
| Document: 0001171843-26-003344-index-headers.html | 0001171843-26-003344 |
| Document: 0001171843-26-003344-index.html | 0001171843-26-003344 |
| Document: 0001171843-26-003344.txt | 0001171843-26-003344 |
| 8-K Data (Synthetic) | 0001171843-26-003344 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
5d ago
|
8-K
| $1.71 $1.71 | · 0.00% | ▲ +2.60% | $1.72 (+0.58%) |
|
Jun 2, 2026
7d ago
|
Press Release
| $1.70 $1.74 | ▲ +2.35% | ▲ +3.07% | $1.72 (+1.18%) |
|
May 13, 2026
27d ago
|
8-K
| $1.45 $1.47 | ▲ +1.38% | ▲ +0.60% | $1.72 (+18.62%) |
|
May 13, 2026
27d ago
|
Press Release
| $1.45 $1.47 | ▲ +1.38% | ▲ +0.60% | $1.72 (+18.62%) |
|
Mar 25, 2026
10w ago
|
Press Release
| $1.61 $1.60 | ▼ −0.62% | ▲ +1.06% | $1.72 (+6.83%) |
|
Mar 25, 2026
10w ago
|
Press Release
| $1.68 $1.61 | ▼ −4.17% | ▼ −2.40% | $1.72 (+2.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access